Translation of virtual-pinhole magnifying PET technology to clinical whole-body cancer imaging

虚拟针孔放大PET技术在临床全身癌症成像中的转化

• 批准号: 10305587
• 负责人: YUAN-CHUAN TAI
• 金额: $ 53万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-12-04 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10305587
• 关键词: Address; Adopted; Beds; Cancer Detection; Cancer Patient; Clinic; Clinical; Clinical Research; Computed Tomography Scanners; Computer software; Costs and Benefits; Data; Data Set; Detection; Development; Devices; Diagnostic Neoplasm Staging; Diagnostic Sensitivity; Discipline of Nuclear Medicine; Disease; Disease Management; Disseminated Malignant Neoplasm; Distant Metastasis; Emission-Computed Tomography; Funding; Image; Image Enhancement; Imaging technology; Institution; Knowledge; Lesion; Letters; Location; Magnetic Resonance Imaging; Monitor; Motion; Multi-Institutional Clinical Trial; Neoplasm Metastasis; Noise; Nuclear Radiology; Outcome; Patients; Physicians; Positioning Attribute; Positron-Emission Tomography; Principal Investigator; Protocols documentation; Radiology Specialty; Research; Research Personnel; Resolution; Scanning; Signal Transduction; Staging; Surface; System; Technology; Thigh structure; Time; Translating; Translations; Uncertainty; Universities; Validation; Vision; Washington; X-Ray Computed Tomography; accurate diagnosis; attenuation; cancer diagnosis; cancer imaging; cancer type; cost effective; cranium; detection method; detection sensitivity; detector; diagnostic accuracy; human imaging; image reconstruction; imaging capabilities; imaging detection; imaging study; improved; in vivo imaging; innovation; interest; medical schools; molecular imaging; novel; novel imaging technology; programs; prototype; standard of care; statistics; success; technology development; treatment response; virtual; whole body imaging

Project Summary / Abstract FDG whole-body PET/CT imaging is a proven technique for the detection of primary and metastatic cancers. It is highly accurate and valuate for cancer staging, re-staging, and monitoring response to therapy for many types of cancers. Despite its success and broad clinical utility, there remains an unmet clinical challenge for the detection of small metastatic cancers that are much smaller than 1 cm. FDG PET/CT has been shown to have limited sensitivity for the detection of such small lesions, in some cases less than 50% of the time. We have developed a novel imaging technology called virtual-pinhole magnifying PET technology that can improve the image resolution of clinical PET/CT scanner to enhance its image resolution and to provide zoom- in images without compromising its body imaging capability. While this is a unique capability, it has not been adopted for clinical whole-body cancer imaging because the location of distant metastasis is often unknown. Therefore, one would not have prior knowledge on where to zoom-in during a whole-body imaging protocol. If on the other hand, one needs to scan the entire body first and then chooses a region of high uncertainty to zoom- in; this technology will require a two-step protocol which will significantly slow down clinical workflow. In this project, we formed a bi-directional partnership between the Washington University School of Medicine (WUSM) and Siemens Molecular Imaging (Siemens MI, Knoxville, TN) to overcome this specific limitation and translate an otherwise novel imaging technology to be suitable for clinical utility. We will jointly develop and validate the Augmented Whole-body Scanning via Magnifying PET (AWSM-PET) technology that will enhance the native image resolution of a PET scanner and is fully compatible with clinical whole-body cancer imaging applications. The added device will not slowdown clinical workflow because the magnifying PET data will be acquired simultaneously with the standard PET data when a patient undergoes a whole-body PET/CT scan. In addition to the standard (native) PET/CT images, AWSM-PET will provide a second set of PET images with higher resolution and counting statistics without additional scan time. This information-rich second data set is expected to further improve the diagnostic accuracy of whole-body PET/CT imaging for the detection of metastatic cancer. Upon completion of this project, we will have developed and validated a new capability that can improve the image resolution and counting statistics of a clinical whole-body PET/CT scanner. If the results of the initial human imaging trial show improvement in diagnostic sensitivity for metastatic cancer detection using a whole- body PET/CT equipped with the AWSM-PET technology, we will seek additional funding to conduct a multi- center clinical trial to fully quantify the improvement in diagnostic accuracy by AWSM-PET technology for the detection of metastatic cancers. The success of this novel in vivo imaging technology will address an unmet challenge of the standard-of-care whole-body PET/CT in detecting small metastatic cancers. The WUSM and Siemens MI partnership will accelerate the delivery of the AWSM-PET technology to end users in nuclear medicine and radiology clinics worldwide. Thus the proposed technology development will have highly significant and broad impact on patients who rely on whole-body PET/CT imaging for accurate diagnosis and optimal management of their diseases.

项目摘要 /摘要 FDG全身PET/CT成像是一种检测原发性和转移性癌症的验证技术。它 高度准确且有效，用于癌症分期，重新分期和监测对许多类型的治疗的反应 癌症。尽管它的成功和广泛的临床实用性，但仍未满足的临床挑战 检测小于1厘米的小型转移性癌症。 FDG PET/CT已显示 在某些情况下不到50％的时间，对这种小病变的检测敏感性有限。 我们已经开发了一种新型的成像技术，称为虚拟细胞孔放大宠物技术，可以 改善临床PET/CT扫描仪的图像分辨率，以增强其图像分辨率并提供变焦 在不损害其身体成像能力的图像中。虽然这是一个独特的功能，但还没有 通过临床全身癌症成像采用，因为远处转移的位置通常是未知的。 因此，在全身成像协议中，人们将没有关于在何处缩放的先验知识。如果 另一方面，需要先扫描整个身体，然后选择一个高度不确定性的区域以缩放 - 在;该技术将需要两步协议，这将大大减慢临床工作流程。 在这个项目中，我们在华盛顿大学医学院之间建立了双向伙伴关系 （WUSM）和西门子分子成像（Siemens Mi，田纳西州诺克斯维尔），以克服这一特定限制和 翻译出一种新颖的成像技术，以适合临床实用性。我们将共同发展并 通过放大宠物（AWSM-PET）技术验证增强的全身扫描，该技术将增强 PET扫描仪的天然图像分辨率，并且与临床全身癌症成像完全兼容 申请。添加的设备不会放缓临床工作流程，因为放大的宠物数据将是 当患者接受全身PET/CT扫描时，与标准PET数据同时获得。在 除标准（本地）PET/CT图像外，AWSM-PET将提供第二组PET图像 没有额外的扫描时间，更高的分辨率和计数统计信息。此信息丰富的第二个数据集是 预计将进一步提高全身PET/CT成像的诊断准确性以检测 转移性癌。 该项目完成后，我们将开发并验证了可以改善的新功能 临床全身PET/CT扫描仪的图像分辨率和计数统计数据。如果初始结果 人类成像试验显示，使用整个 - 配备AWSM-PET技术的身体宠物/CT，我们将寻求额外的资金来进行多种资金 中心临床试验，以充分量化AWSM-PET技术诊断准确性的提高 检测转移性癌症。这部小说中的体内成像技术的成功将解决未成熟的 在检测小型转移性癌症时，挑战现有的全身PET/CT。 WUSM 西门子MI合作伙伴关系将加速AWSM-PET技术以最终的核用户 全球医学和放射诊所。因此，拟议的技术开发将具有非常重要的 对依靠全身PET/CT成像的患者进行广泛影响，以准确诊断和最佳 管理他们的疾病。